Insight Molecular Diagnostics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IMDX Nasdaq 2836 www.imdxinc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing - Aug 11th, 2026 2:05 pm
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary - Aug 11th, 2026 6:30 am
Oncocyte Q2 Earnings Call Highlights - Aug 10th, 2026 6:04 pm
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx - Aug 10th, 2026 2:05 pm
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - Aug 4th, 2026 5:00 am
iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication - Jul 23rd, 2026 6:00 am
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio - Jul 16th, 2026 1:22 pm
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper - Jun 29th, 2026 6:00 am
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant - Jun 22nd, 2026 12:07 pm
​Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment - Jun 19th, 2026 12:17 pm
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry - Jun 16th, 2026 2:05 pm
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation - Jun 11th, 2026 2:17 pm
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress - Jun 9th, 2026 2:05 pm
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission - May 15th, 2026 7:16 am
Insight Molecular Diagnostics Inc. Q1 2026 Earnings Call Summary - May 14th, 2026 6:30 am
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call Highlights: Strategic Advances ... - May 13th, 2026 11:00 pm
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization - May 13th, 2026 2:05 pm
iMDx to Release First Quarter 2026 Results on May 13, 2026 - May 6th, 2026 2:05 pm
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones - Apr 28th, 2026 6:18 pm
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay - Apr 14th, 2026 6:00 am